Honesty the only policy that matters, says Wellcome Trust’s Nicholas Moakes

The chief investment officer of the London-based $71bn Wellcome Trust, Nick Moakes, has a simple rule for the trust’s investment team: “Never invest with anyone who is or has been or should have been in prison.”
Wellcome Trust chief investment officer Nicholas Moakes. Picture: Steven Pocock

Glenda Korporaal

Honesty the only policy that matters, says Wellcome Trust’s Nicholas Moakes

September 5, 2024
The chief investment officer of the London-based $71bn Wellcome Trust, Nick Moakes, has a simple rule for the trust’s investment team: “Never invest with anyone who is or has been or should have been in prison.”
Read Transcript

The chief investment officer of the London-based $71bn Wellcome Trust, Nick Moakes, has a simple rule for the trust’s investment team: “Never invest with anyone who is or has been or should have been in prison.”

‍When it comes to looking at companies to invest in, says Moakes, who will deliver a keynote address to the Sohn Hearts & Minds conference in Adelaide on November 15, the culture of the business is key.

‍“We are obsessive about the culture of the organisations we invest in,” says Moakes, who has been CIO of the trust for seven years. “For us, culture trumps strategy every day of the week.”

‍Chaired by former prime minister Julia Gillard, the Wellcome Trust is one of the world’s largest philanthropic foundations, set up with funds from the estate of medical entrepreneur and philanthropist Sir Henry Wellcome in 1936.

‍The trust, which donates more than $2bn a year to support medical research, has delivered average annual returns of 12.3 per cent over the past decade.

‍More than 25 per cent of the trust is invested in global equities with holdings in blue chip companies including Alphabet, Amazon, Nestle, Microsoft and Visa.

‍It funds research into mental health, infectious diseases and climate, and the health impact of climate change.

‍It has similar goals to the Sohn Hearts & Minds conference which is now in its ninth year in Australia, having raised $70m for medical research since its launch in 2016, founded by former UBS bankers Matthew Grounds and Guy Fowler, and businessman Gary Weiss.

‍Attendees at the Sohn conference pay to hear stock tips and the investment strategies from some of the world’s top fund managers, with the funds raised going to medical research organisations such as the Victor Chang Cardiac Research Institute, The Brain and Mind Centre at Sydney University, and the Walter and Eliza Hall Institute of Medical Research in Melbourne.

This year’s speakers will include the co-chair and co-founder of Oaktree Capital, Howard Marks, the managing partner of the US-based Scalar Gauge Fund, Sumit Gautam, Sydney fund manager Alex Pollak, the founder of Loftus Peak, IFM Investors portfolio manager Rikki Bannan, and Terra Capital Founder and chief investment officer Jeremy Bond.‍

More than 600 people have already signed up to attend conference, with half of the funds raised going to the South Australian Health and Medical Research Institute‍

Moakes, who will retire from his role in March 2025 after 17 years with the trust, says he was attracted to the Sohn conference because of its similarity to the work of the trust.‍

He carefully avoids giving any specific examples of how he has applied his don’t-invest-in-criminals strategy, but his message is clear: investing in companies with dubious reputations is too risky.

Investing only in reputable companies or ventures is important for the Wellcome Trust’s reputation as well as its investment performance.

Unlike other funds, such as the Bill and Melinda Gates Foundation, the trust has no time limit.

“We invest with an infinite time horizon,” says Moakes. “We get no grants from government. We don’t accept donations from individuals.

‍“Our liquidity is entirely generated from this portfolio.”‍

The trust has given a commitment that it will spend more than $30bn on medical research over the 10 years from 2032. It has spent $5.3bn in the first two years, but it plans to pick up the pace.

That pledge means that while it can invest for the long term, it has to do so with an eye on cash flow. “One of our criteria in assessing investments is how likely are we to lose our capital – permanent loss of capital after inflation?” Moakes says.‍

Under Moakes, the trust has sought to capitalise on its longevity and its AAA credit rating, taking the pioneering approach of issuing long-dated bonds starting with 100-year bonds in 2018 and 50-year bonds in 2021.

‍Moakes says the fund’s aim is to “maximise our take from global GDP”, an approach which he acknowledges “gives you a very large blank piece of paper”.

‍The trust has no specific asset allocation approach looking at listed and unlisted investments around the world on their merits.

‍All of its property is in the UK, but half of its share investment is in the US.

‍The fund has 38 per cent in listed shares, 35 per cent in private equity, 11 per cent with hedge funds, 9 per cent in cash and bonds, and 8 per cent in property.

‍Information technology is the biggest single sector, making up 27 per cent, followed by consumer discretionary and health care at 15 per cent each, with 14 per cent in financials.‍

Moakes says managers at the Wellcome Trust spend most of their time focusing on the investments it already owns and only a small proportion looking at potential new investments.

‍“A lot of the investment world is about FOMO – fear of missing out – about managers looking at the things they don’t own and saying they should have got into it earlier,” he says. “What we are focused on is delivering absolute returns over the long term. We own assets that we are confident will deliver that and they will do it in a way that we understand them, and they meet our criteria about responsible investment.”

‍Moakes says all the trust’s property is based in the UK as it is the region its managers know best. But when it comes to other investments, both private and public, he has a strong bias to the US because of its deep capital markets and the strength of its innovation culture which has seen the emergence of companies such as the Magnificent Seven.

‍“The reason the US has been able to maintain superior economic growth is partly because it has attracted labour to come in through immigration, but largely it has been through productivity growth which is all about innovation,” he says.

‍Over the long term, he argues that investors can get a good return by investing in shares provided they keep their head in times of volatility and don’t indulge in panic selling at the bottom of the market.

‍“Over the long term, if you have invested in shares and reinvested the dividends you have got 5 per cent a year real return from equities,” he says.

Moakes began his career as a diplomat with the UK government working in the UN and then Hong Kong in the years leading up to the handover to China in 1997. An interest in studying the economic impact of the opening up of China had him join Blackrock as an investment analyst.

‍He rose to the position of head of BlackRock’s Asia Pacific investment team and co-head of emerging markets before joining Wellcome in 2007.

‍This week he announced plans to retire from his role in March, stepping back to a role of emeritus partner and adviser.

‍Moakes says he has had “the best investment job in the world”.

‍“There are very few places where investments can be made on a multi-decade view, where there is freedom to invest across asset classes, where proper account is taken of environmental and social perspectives, and where you can do it all for a vital mission like Wellcome’s,” he says.

‍Moakes says his invitation to speak at Sohn in Adelaide came from a former Hong Kong friend who now lives in Sydney, and not Julia Gillard whose hometown was Adelaide, but he says Gillard has given him some handy tips on what to see and do in the city.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on 5 November 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

The chief investment officer of the London-based $71bn Wellcome Trust, Nick Moakes, has a simple rule for the trust’s investment team: “Never invest with anyone who is or has been or should have been in prison.”

‍When it comes to looking at companies to invest in, says Moakes, who will deliver a keynote address to the Sohn Hearts & Minds conference in Adelaide on November 15, the culture of the business is key.

‍“We are obsessive about the culture of the organisations we invest in,” says Moakes, who has been CIO of the trust for seven years. “For us, culture trumps strategy every day of the week.”

‍Chaired by former prime minister Julia Gillard, the Wellcome Trust is one of the world’s largest philanthropic foundations, set up with funds from the estate of medical entrepreneur and philanthropist Sir Henry Wellcome in 1936.

‍The trust, which donates more than $2bn a year to support medical research, has delivered average annual returns of 12.3 per cent over the past decade.

‍More than 25 per cent of the trust is invested in global equities with holdings in blue chip companies including Alphabet, Amazon, Nestle, Microsoft and Visa.

‍It funds research into mental health, infectious diseases and climate, and the health impact of climate change.

‍It has similar goals to the Sohn Hearts & Minds conference which is now in its ninth year in Australia, having raised $70m for medical research since its launch in 2016, founded by former UBS bankers Matthew Grounds and Guy Fowler, and businessman Gary Weiss.

‍Attendees at the Sohn conference pay to hear stock tips and the investment strategies from some of the world’s top fund managers, with the funds raised going to medical research organisations such as the Victor Chang Cardiac Research Institute, The Brain and Mind Centre at Sydney University, and the Walter and Eliza Hall Institute of Medical Research in Melbourne.

This year’s speakers will include the co-chair and co-founder of Oaktree Capital, Howard Marks, the managing partner of the US-based Scalar Gauge Fund, Sumit Gautam, Sydney fund manager Alex Pollak, the founder of Loftus Peak, IFM Investors portfolio manager Rikki Bannan, and Terra Capital Founder and chief investment officer Jeremy Bond.‍

More than 600 people have already signed up to attend conference, with half of the funds raised going to the South Australian Health and Medical Research Institute‍

Moakes, who will retire from his role in March 2025 after 17 years with the trust, says he was attracted to the Sohn conference because of its similarity to the work of the trust.‍

He carefully avoids giving any specific examples of how he has applied his don’t-invest-in-criminals strategy, but his message is clear: investing in companies with dubious reputations is too risky.

Investing only in reputable companies or ventures is important for the Wellcome Trust’s reputation as well as its investment performance.

Unlike other funds, such as the Bill and Melinda Gates Foundation, the trust has no time limit.

“We invest with an infinite time horizon,” says Moakes. “We get no grants from government. We don’t accept donations from individuals.

‍“Our liquidity is entirely generated from this portfolio.”‍

The trust has given a commitment that it will spend more than $30bn on medical research over the 10 years from 2032. It has spent $5.3bn in the first two years, but it plans to pick up the pace.

That pledge means that while it can invest for the long term, it has to do so with an eye on cash flow. “One of our criteria in assessing investments is how likely are we to lose our capital – permanent loss of capital after inflation?” Moakes says.‍

Under Moakes, the trust has sought to capitalise on its longevity and its AAA credit rating, taking the pioneering approach of issuing long-dated bonds starting with 100-year bonds in 2018 and 50-year bonds in 2021.

‍Moakes says the fund’s aim is to “maximise our take from global GDP”, an approach which he acknowledges “gives you a very large blank piece of paper”.

‍The trust has no specific asset allocation approach looking at listed and unlisted investments around the world on their merits.

‍All of its property is in the UK, but half of its share investment is in the US.

‍The fund has 38 per cent in listed shares, 35 per cent in private equity, 11 per cent with hedge funds, 9 per cent in cash and bonds, and 8 per cent in property.

‍Information technology is the biggest single sector, making up 27 per cent, followed by consumer discretionary and health care at 15 per cent each, with 14 per cent in financials.‍

Moakes says managers at the Wellcome Trust spend most of their time focusing on the investments it already owns and only a small proportion looking at potential new investments.

‍“A lot of the investment world is about FOMO – fear of missing out – about managers looking at the things they don’t own and saying they should have got into it earlier,” he says. “What we are focused on is delivering absolute returns over the long term. We own assets that we are confident will deliver that and they will do it in a way that we understand them, and they meet our criteria about responsible investment.”

‍Moakes says all the trust’s property is based in the UK as it is the region its managers know best. But when it comes to other investments, both private and public, he has a strong bias to the US because of its deep capital markets and the strength of its innovation culture which has seen the emergence of companies such as the Magnificent Seven.

‍“The reason the US has been able to maintain superior economic growth is partly because it has attracted labour to come in through immigration, but largely it has been through productivity growth which is all about innovation,” he says.

‍Over the long term, he argues that investors can get a good return by investing in shares provided they keep their head in times of volatility and don’t indulge in panic selling at the bottom of the market.

‍“Over the long term, if you have invested in shares and reinvested the dividends you have got 5 per cent a year real return from equities,” he says.

Moakes began his career as a diplomat with the UK government working in the UN and then Hong Kong in the years leading up to the handover to China in 1997. An interest in studying the economic impact of the opening up of China had him join Blackrock as an investment analyst.

‍He rose to the position of head of BlackRock’s Asia Pacific investment team and co-head of emerging markets before joining Wellcome in 2007.

‍This week he announced plans to retire from his role in March, stepping back to a role of emeritus partner and adviser.

‍Moakes says he has had “the best investment job in the world”.

‍“There are very few places where investments can be made on a multi-decade view, where there is freedom to invest across asset classes, where proper account is taken of environmental and social perspectives, and where you can do it all for a vital mission like Wellcome’s,” he says.

‍Moakes says his invitation to speak at Sohn in Adelaide came from a former Hong Kong friend who now lives in Sydney, and not Julia Gillard whose hometown was Adelaide, but he says Gillard has given him some handy tips on what to see and do in the city.

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on 5 November 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Disclaimer: This material has been prepared by The Australian, published on Sep 05, 2024. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
July 21, 2024

Investors ‘comfortable’ about a Trump presidency, despite volatility

Economists and market experts say the outcome of the US presidential election has been largely priced in by investors as softening inflation helps to buoy sharemarkets both globally and locally.

Read More
Qiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar ColmanQiao Ma, portfolio manager at Munro Partners, says the Nvidia rally is nowhere close to being over. Picture: Oscar Colman
May 28, 2024

The AI bulls are sticking to Nvidia despite 600pc share price rally

Nvidia’s quarterly earnings once again exceeded analysts’ expectations and Portfolio Manager, Qiao Ma of Munro Partners says the rise is “nowhere close to being over”.

Read More
Munro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke MeitzelMunro Partners' Kieran Moore likes US Tex-Mex fast food operator Chipotle, and Meta. Picture: Elke Meitzel
February 15, 2024

Hedge fund Munro says Nvidia, Microsoft have more to run

Kieran Moore is portfolio manager of Munro Partners Global Growth Fund. The Melbourne-based hedge fund oversees $4.3 billion in assets.

Read More
January 24, 2024

How To Master The Art Of Winning The Room

Jonathan Pease, the creative director behind the Sohn Hearts & Minds Conference and author of the book, Winning the Room, recently sat down for a chat with Mark Bouris on Straight Talk.

Read More
2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 2023’s winners: DigitalX’s Lisa Wade, Jason Orthman from Hyperion, Regal Partner’s Todd Guyot, and Cathie Wood of ARK Investment. 
January 19, 2024

Best funds of 2023 stick with bitcoin, big tech bets

Some of the best performing funds of 2023 are holding firm on bitcoin and mega-cap tech stock picks that made them big money last year.

Read More
November 19, 2023

Equity Mates review the stocks pitched at the Sohn Hearts & Minds Conference

Bryce and Ren of Equity Mates attended the Sohn Hearts & Minds Conference and reviewed the stocks pitched by our new 2023 Conference Fund Managers.

Read More
Ark Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David RoweArk Invest CEO Cathie Wood remains as big-picture as ever. Picture: David Rowe
November 17, 2023

‘I Know It Sounds Crazy’: Cathie Wood’s Next Big Idea

Speaking from Ark’s headquarters in Florida ahead of her appearance at the Sohn Hearts & Minds Conference on Friday, Wood says she believes disinflation is now just around the corner in the US.

Read More
ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.ARK Invest founder Cathie Wood: It does appear that the SEC here in the United States is likely to approve a spot bitcoin ETF within the next few months.
November 17, 2023

ARK Founder Wood Backs Bitcoin, Banking On Spot ETF Approval

Tech investment guru Cathie Wood is still a big believer in bitcoin, so it was fitting that she chose Grayscale Bitcoin Trust as her stock pick for the 2023 Sohn Hearts & Minds Investment Leaders Conference.

Read More
IFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee NowytargerIFM Investors small cap specialist Rikki Bannan addresses the Sohn Hearts & Minds Investment Leaders Conference at Sydney Opera House. Picture: Renee Nowytarger
November 17, 2023

Hot Stocks To Ride The Next Healthcare Trends

Healthcare stocks – from sleep apnoea giant ResMed, to cancer diagnostic biotech Telix Pharmaceuticals – were recommended at the Sohn Hearts & Minds Investment Leaders Conference on Friday.

Read More
November 17, 2023

How Daniel Loeb, The Real Bobby Axelrod, Made His Wall Street Billions

When Damian Lewis, the actor who plays the ruthless hedge fund boss in the drama series Billions was looking for inspiration, he sat down with Daniel Loeb.

Read More
November 17, 2023

The 12 Hottest Stock Tips From This Year’s Sohn Experts

It might be time to look beyond big names. That was the message from top fund managers, company founders and super funds at the Sohn Hearts & Minds.

Read More
Azora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee NowytargerAzora Capital founder Ravi Chopra. Picture: Renee Nowytarger
November 17, 2023

Webster Financial ‘Avoided The Mistakes Of US Bank Failures’

The US financial sector is not without its problems but Ravi Chopra backs Webster Financial Corporation as his stock pick for the 2023 Sohn Hearts & Minds Investment Leaders Conference.

Read More
November 17, 2023

Why Stock Picker Cathie Wood Of ARK Can’t Stand Google

The world’s highest-profile tech investor, Cathie Wood, might be bruised but she is certainly bullish. Nor is she holding back.

Read More
Munro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee NowytargerMunro Partners partner and portfolio manager Kieran Moore at the Sohn Hearts & Minds conference in Sydney. Picture: Renee Nowytarger
November 17, 2023

Wise Share Price Could Rise 50pc By 2025, Says Munro Partners

Global growth fund manager Munro has about $4.3bn in funds under management across four global funds, and usually invests in companies that are poised to win from massive structural change.

Read More
Martin Hughes founder of UK-based Toscafund. Picture: Elke MeitzelMartin Hughes founder of UK-based Toscafund. Picture: Elke MeitzelMartin Hughes founder of UK-based Toscafund. Picture: Elke MeitzelMartin Hughes founder of UK-based Toscafund. Picture: Elke Meitzel
November 16, 2023

Hedge Fund Veteran Talks Lowest Moment In Toscafund’s 23-Year Run

Most hedge fund managers brag about their wins and shy away from their losses – Martin Hughes is not most hedge fund managers.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.